^
No biomarker
Small Lymphocytic Lymphoma
ICP-022
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
rituximab + ibrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A1 - Approval
No biomarker
Small Lymphocytic Lymphoma
PCR
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
FCR
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
chlorambucil
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
CD20 inhibitor
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
ofatumumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
lenalidomide
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
OFAR
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
R-CVAD
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
EPOCH-R
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
R-CHOP
Sensitive: A2 - Guideline
Chr del(17p)
Small Lymphocytic Lymphoma
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
Small Lymphocytic Lymphoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
BR
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
BR + ibrutinib
Sensitive: A2 - Guideline
No biomarker
Small Lymphocytic Lymphoma
BR + idelalisib
Sensitive: A2 - Guideline
TP53 deletion
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: A2 - Guideline
BIRC3 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: B - Late Trials
IGH mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: B - Late Trials
Chr del(11q)
Small Lymphocytic Lymphoma
ibrutinib
Sensitive: B - Late Trials
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: B - Late Trials
TP53 mutation + Chr del(17p)
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
TP53 mutation
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
TP53 mutation + Chr del(17p)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
TP53 mutation
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
Chr del(11q)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
obinutuzumab + zanubrutinib
Sensitive: C3 – Early Trials
IGH mutation
Small Lymphocytic Lymphoma
FCR
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
FCR
Sensitive: C3 – Early Trials
Chr del(17)(p13.1)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: C3 – Early Trials
Chr del(11)(q22.3)
Small Lymphocytic Lymphoma
acalabrutinib
Sensitive: C3 – Early Trials
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
Chr del(17p)
Small Lymphocytic Lymphoma
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
ATM mutation
Small Lymphocytic Lymphoma
T-lymphocyte cell therapy
Sensitive: C4 – Case Studies